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Background: Measurement uncertainty characterizes the dispersion of the quantity values attributed to a measurand. Although 
this concept was introduced to medical laboratories some years ago, not all medical researchers are familiar with it. Therefore, the 
evaluation and expression of measurement uncertainty must be highlighted using a practical example.
Methods: In accordance with the procedure for evaluating and expressing uncertainty, provided by the Joint Committee for 
Guides in Metrology (JCGM), we used plasma glucose (Glu) as an example and defined it as the measurand. We then analyzed the 
main sources of uncertainty, evaluated each component of uncertainty, and calculated the combined uncertainty and expanded 
uncertainty with 2 budgets for single measurements and continuous monitoring, respectively.
Results: During the measurement of Glu, the main sources of uncertainty included imprecision, within-subject biological variance 
(BVw), calibrator uncertainty, and systematic bias. We evaluated the uncertainty of each component to be 1.26%, 1.91%, 5.70%, 
0.42%, and -2.87% for within-run imprecision, between-day imprecision, BVw, calibrator uncertainty, and systematic bias, respec-
tively. For a single specimen, the expanded uncertainty was 7.38% or 6.1±0.45 mmol/L (κ=2); in continuous monitoring of Glu, 
the expanded uncertainty was 13.58% or 6.1±0.83 mmol/L (κ=2).
Conclusions: We have demonstrated the overall procedure for evaluating and reporting uncertainty with 2 different budgets. The 
uncertainty is not only related to the medical laboratory in which the measurement is undertaken, but is also associated with the 
calibrator uncertainty and the biological variation of the subject. Therefore, it is helpful in explaining the accuracy of test results.
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INTRODUCTION
Error and error analysis have long been a part of practice 
in medical laboratories. The classic error theory comprises 
random error and systematic error. The random error is the 
component of measurement error that, in replicate mea-
surements, varies in an unpredictable manner, whereas the 
systematic error is the component of measurement error 
that, in replicate measurements, remains constant or varies 
in a predictable manner [1]. Thus, the random error can be 
estimated using frequency-based statistics, but the system-
atic error cannot be estimated using statistical methods. 
Therefore, error analysis, which includes statistical and non-
statistical procedures, leads to inconsistencies in data analy-
sis, particularly in error propagation [2]. Additionally, it is 
impossible to measure a routine specimen more than a cer-
tain number of times in a medical laboratory. Therefore, the 
classic theory of error is no longer suitable for the actuality 
of laboratory medicine.
Measurement uncertainty is a non-negative parameter 
characterizing the dispersion of the quantity values being 
attributed to a measurand [1]. Although introduced in the 
1960s, the evaluation and expression of measurement un-
certainty were only generally accepted in the 1990s. The 
medical community is not yet familiar with this new con-
cept [3]. When faced with the requirements of accredita-
tion, medical laboratory researchers are unsure how to eva-
luate the uncertainty of measurement. Meanwhile, numer-168     www.kjlm.org
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ous studies have debated its practical application [4-6]. For 
example, there are no accepted criteria for which compo-
nents should be introduced into measurement uncertainty. 
Therefore, training and explanations are necessary to intro-
duce this concept into routine practice [3].
Plasma glucose (Glu) is an important laboratory marker 
for diabetes mellitus. Clinical doctors and patients pay close 
attention to the concentration of Glu. In this study, the mea-
surement of Glu was used as an example to demonstrate the 
procedure of evaluating uncertainty, and 2 budgets have 
been designed to combine the measurement uncertainty ac-
cording to different measurement purposes.
MATERIALS AND METHODS
1. Materials
A Roche automatic biochemical analyzer (DDP; Roche 
Diagnostics, Penzberg, Germany) was used. Reagents, con-
trol materials, and the calibrator for Glu were also from 
Roche Diagnostics. The control materials were measured 
for the imprecision data. The proficiency test was organized 
by the College of American Pathologists (CAP). Biological 
variation documentation was obtained from the Westgard 
website [7].
2. Evaluation methods
1) Definition of the measurand
From January to September 2010, plasma Glu was mea-
sured by the glucose hexokinase method in our laboratory, 
which was accredited by ISO 15189 (Certification Number: 
CNAS MT0034).
2) Identifying the sources of uncertainty
The main sources of uncertainty are analyzed in Fig. 1 and 
are shown to come from pre-analysis and analysis.
(1) Pre-analysis
In pre-analysis, the sources of uncertainty included sub-
ject preparation, specimen collection, storage, and centrifu-
gation. In the medical laboratory, the within-subject biolog-
ical variance (BVw) of the subject is an important source and 
should not be neglected for individuals whose Glu is con-
tinuously monitored. We obtained the BVw data from the 
Westgard website [7]. However, in cases where there was a 
single specimen, no BVw could be calculated. The process of 
specimen preparation and storage could influence the result 
of the measurement. However, these factors can be reduced 
to a minimum by strictly executing the standard operating 
procedure.
(2) Analysis
Before measurement, the measurement system must be 
calibrated. According to the traceability reports, the mea-
surement of Glu traces to the reference method of isotope-
dilution mass spectrometry (ID-MS). Because different lev-
els of uncertainty in the calibrator will give rise to different 
uncertainty results, this uncertainty was evaluated as type B 
according to the uncertainty report provided by the manu-
facturer. Additionally, systematic bias is a factor affecting 
the accuracy of measurement. We evaluated the uncertainty 
of systematic bias according to the reports of the CAP pro-
ficiency test.
In the analytical process, many components of uncertain-
ty, such as the repeatability of the absorbance, the stability of 
room temperature and humidity, and changes of operator 
and reagent lots, were involved. Fortunately, all these could 
be represented by imprecision. As shown in Fig. 1, we calcu-
lated the within-run imprecision and between-day impreci-
sion to represent the uncertainty caused by these factors.
3) Evaluation of the component of uncertainty [μ(χ
i)]
(1) Type A evaluation
According to the International Vocabulary of Metrology 
(VIM), type A evaluation is based on a statistical analysis of 
measured quantity values obtained under defined measure-
ment conditions [1]. Among all the above sources of uncer-
tainty, the uncertainty of within-run imprecision [μ(χ
within-run)] 
and between-day imprecision [μ(χ
between-day)] belong to type A.
(2) Type B evaluation
According to VIM, type B evaluation is determined by 
means other than a type A evaluation [1]. Type B includes 
the following sources of uncertainty. (i) BVw: the data was 
quoted from the Westgard website [7] and the uncertainty 
[μ(χ
BVw)] was calculated. (ii) Calibrator: according to the re-
port of traceability and uncertainty provided by Roche Di-
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Fig. 1. Cause and effect diagram for uncertainty of glucose (Glu) measure-
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agnostics, when the calibrator value of Glu was 10.70 mmol/
L, the uncertainty was 0.0905 mmol/L (κ=2). We calculated 
the uncertainty [μ(χ
calibrator)] according to the data. (iii) Sys-
tematic bias: according to EP-15A [8], the regression equa-
tion was constructed between the means of the proficiency 
test and the results of our lab (10 CAP survey data points, 
twice in 2010). Because the intercept denotes the fixed er-
rors, we obtained the systematic bias [μ(χ
bias)] by setting the 
intercept as zero.
4) Determination of the combined uncertainty [μc(y)]
After evaluating each component of uncertainty [μ(χ
i)], 
all the components were combined. The combined uncer-
tainty [μc(y)] is equal to the positive square root of a sum of 
terms [1], and the combined standard uncertainty of Glu 
should be calculated as shown below:
In this study, because all the components of uncertainty 
were relative quantities, we changed the computational for-
mula as follows:
There is no agreement on whether BVw should be com-
bined in a medical laboratory. According to the different 
purposes of measurement, we designed 2 budgets to com-
bine the standard uncertainty. For a single specimen, bud-
get 1 included imprecision, calibrator uncertainty, and bias; 
for those individuals who required consecutive monitoring, 
the BVw should be added as budget 2.
5) Calculation of the expanded uncertainty (U)
According to VIM, the expanded uncertainty (U) equals 
to the product of a combined uncertainty and a coverage 
factor (κ) larger than the number 1 [1]. In medical labora-
tories, κ is generally set to 2, which is associated with a cov-
erage probability of 95%. So U(Glu)=2×μc(Glu).
 
RESULTS
1. The components of uncertainty
1) Type A
According to the results of the within-run imprecision 
analysis, the μ(χ
within-run) was calculated as 1.26% (mean=6.77 
mmol/L, n=20). Moreover, the μ(χ
between-day) was 1.91% (me-
an=6.71 mmol/L, n=20).
μc(Glu)=[μ
2(χ
within-run)+μ
2(χ
between-day)+μ
2(χ
BVw)+μ
2(χ
calibrator)+μ
2(χ
bias)]
½
μc(Glu)
=[(
μ(χ
within-run)
)
2+(
μ(χ
between-day)
)
2+(
μ(χ
BVw)
)
2+(
μ(χ
calibrator)
)
2+(
μ(χ
bias)
)
2]
½
       Glu             χ
within-run
                         χ
between-day
                        χ
BVw
                          χ
calibrator
                        χ
bias
   
2) Type B
The components of type B included BVw, calibrator unce-
rtainty, and bias. The sources and uncertainty of each com-
ponent are listed in Table 1.
2. The combined uncertainty
1) Budget 1
For a single specimen, the BVw component was not taken 
into consideration; therefore, the computational formula-
tion for combined uncertainty was: 
μC(Glu)=[1.26
2+1.91
2+0.42
2+(-2.87)
2]
½=3.69%
2) Budget 2
The BVw was added, and the computational formulation 
for combined uncertainty was changed to
μC(Glu)=[1.26
2+1.91
2+5.7
2+0.42
2+(-2.87)
2]
½=6.79%
3. The expanded uncertainty
According to the characteristics and requirements of the 
medical laboratory, we set the coverage factor (κ) to 2 with 
a coverage probability of 95%. Therefore, U=μc(Glu)×κ.
In this study, in order to combine the components of un-
certainty, the relative uncertainty was used initially, and the 
expanded uncertainty was thus the relative expanded uncer-
tainty (Urel). Generally, since patients and doctors pay great 
attention to the upper limit of a reference interval, we took 
6.1 mmol/L as an example to calculate the expanded uncer-
tainty (U). For budget 1, Urel=3.69%×2=7.38%, or U=6.1 
mmol/L×7.38%=0.45 mmol/L; for budget 2, Urel=6.79%× 
2=13.58%, or U=6.1 mmol/L×13.58%=0.83 mmol/L.
We have listed all the uncertainties in this study in Table 2.
DISCUSSION
The development of measurement uncertainty has come 
μc(Glu)
=[(
μ(χ
within-run)
)
2+(
μ(χ
between-day)
)
2+(
μ(χ
BVw)
)
2+(
μ(χ
calibrator)
)
2+(
μ(χ
bias)
)
2]
½
      Glu              χ
within-run 
                        χ
between-day
                    χ
BVw
                   χ
calibrator
                        χ
bias
   
Table 1. Uncertainty of type B
Sources of 
component Referenced document Relative uncertainty 
(μrel, κ=1)
BVw Westgard website 5.70%
Calibrator Roche Diagnostics 0.42%
Systematic bias CAP proficiency test reports of 2010 -2.87% 
Abbreviation: BVw, within-subject biological variance.
μc(Glu)
=[(
μ(χwithin-run)
)
2+(
μ(χ
between-day)
)
2+(
μ(χ
calibrator)
)
2+(
μ(χ
bias)
)
2]
½
       
Glu             χ
within-run
                         χ
between-day
                        χ
calibrator
                        χ
bias
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a long way. In 1963, the National Institute of Standards and 
Technology (NIST) suggested that the uncertainty should 
be expressed in quantitative methods, but no more detail on 
usage and expression was provided. In 2008, the Working 
Group 1 of the JCGM (JCGM/WG1) published the latest 
version of the Guide to the Expression of Uncertainty in 
Measurement (GUM), and it became the conventional stan-
dard for expressing the uncertainty of measurement [9]. 
However, the concept of uncertainty is still relatively new in 
the field of quantity measurement, particularly in the medi-
cal laboratory. Therefore, in the present study, we have high-
lighted the evaluation and expression of uncertainty using a 
practical example.
With the development and standardization of clinical 
medicine, doctors and patients are expecting high-quality 
test results, which is a challenge to the medical laboratory. 
The measurement uncertainty may assist in facing this chal-
lenge; however, the process of measurement has been restri-
cted by multiple factors such as reference measurements, 
the values assigned to the calibrator, the methods of calibra-
tion, and the preparation of subjects, not all of which can be 
controlled in a medical laboratory. These factors have evok-
ed a dispute regarding the use of uncertainty in medical 
laboratories. Some experts in laboratory medicine have 
even expressed doubt regarding the applicability and use-
fulness of uncertainty in routine tests carried out by medi-
cal laboratories [4, 5].
In this study, we chose the measurement of Glu to dem-
onstrate the application of uncertainty in routine tests. Fol-
lowing the evaluation procedures recommended by JCGM 
[9], we identified the sources of uncertainty and evaluated 
the components as type A and type B. While identifying the 
source of uncertainty, we took into account the accuracy of 
values assigned to the calibrator, because occasionally, the 
calibrator lot change leads to the violation of inner quality 
control. With regard to the physiological variation within 
an individual, this is very important for diabetics who re-
quire consecutive Glu monitoring. Consequently, we took 
the BVw into consideration in budget 2. However, other po-
tential uncertainty factors in pre- and post-analysis (for ex-
ample, poor specimen collection or transportation, the pre-
sence of drugs in the patient, and clerical and reporting er-
rors), do not affect the inherent uncertainty of the testing 
procedure itself [10], because we could control these factors 
well if all staff performed the tests in strict accordance with 
standard operating procedure. Therefore, these factors were 
excluded from the procedure for evaluating uncertainty.
The concentration of Glu is important for both endocrino-
logists and diabetics, particularly when the concentration is 
close to the upper limit of the reference interval (6.1 mmol/
L). We should apply different budgets of uncertainty to ex-
plain the accuracy and variation of Glu depending on the 
measurand. If the measurand is the plasma Glu taken from 
a patient at a specific time, then budget 1 is suitable. If the 
measurand is the plasma Glu taken from a patient who 
monitors his/her Glu concentration continuously over a 
time period, then the BVw becomes of interest, and budget 2 
could be used, for example, if the specimen was from a pa-
tient taking the oral glucose tolerance test. In addition to the 
uncertainty, we should notify doctors and patients that κ=2 
is generally associated with a coverage probability of 95%.
In summary, complying with the latest procedures pro-
vided by JCGM, we have demonstrated the overall process 
of evaluating uncertainty and designed 2 budgets to com-
bine the uncertainty for different purposes. We hope that 
this can promote the use of measurement uncertainty in 
medical laboratories and can help doctors and patients to 
better understand the accuracy of results.
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